Technology area: Biotechnology & Pharmaceuticals
1 pending office actions • 1 art units • 1 examiners • 0 of 1 (0%) have an AI response strategy ready • 4 patents granted in the last 365 days
Statens Serum Institut is currently managing 2 pending office actions in the Biotechnology & Pharmaceuticals technology area. These actions are split between 2 distinct examiners, meaning each pending matter is under the review of a different individual. This distribution suggests that the pending applications may involve distinct biological or pharmaceutical inventions.
The portfolio also spans 2 distinct art units, matching the number of examiners and pending actions. BROWE, DAVID is the busiest examiner, currently responsible for 1 busiest examiner pending action. Because 1 of the 2 pending actions is assigned to this examiner, practitioners must coordinate their prosecution strategy across two different specialized groups within the patent office.
Based on the USPTO statutory response window for each pending office action. 1 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| Multi-statute (no §101) | 1 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| SABOUR, GHAZAL | 1 | 34.2% | +35.0% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17207541 | Methods for Evaluation of Gestational Progress and Preterm Abortion for Clinical Intervention and Applications Thereof | SABOUR, GHAZAL | 9d |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17207541 | Methods for Evaluation of Gestational Progress and Preterm Abortion for Clinical Intervention and Applications Thereof | SABOUR, GHAZAL | 9d |
| Art Unit | Apps |
|---|---|
| 1686 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 17207541 | Methods for Evaluation of Gestational Progress and Preterm Abortion for Clinical Intervention and Applications Thereof | SABOUR, GHAZAL | 1686 | §103§112 | Non-Final OA | 9d | Pending | Mar 19, 2021 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialStatens Serum Institut has 1 pending office actions as of October 2026, spread across 1 art units and 1 examiners.
Ghazal Sabour has the most, with 1 of Statens Serum Institut's pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
